These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 15225829

  • 1. 1,25-Dihydroxyvitamin D downregulation of TGFalpha/EGFR expression and growth signaling: a mechanism for the antiproliferative actions of the sterol in parathyroid hyperplasia of renal failure.
    Dusso A, Cozzolino M, Lu Y, Sato T, Slatopolsky E.
    J Steroid Biochem Mol Biol; 2004 May; 89-90(1-5):507-11. PubMed ID: 15225829
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. A critical role for enhanced TGF-alpha and EGFR expression in the initiation of parathyroid hyperplasia in experimental kidney disease.
    Cozzolino M, Lu Y, Sato T, Yang J, Suarez IG, Brancaccio D, Slatopolsky E, Dusso AS.
    Am J Physiol Renal Physiol; 2005 Nov; 289(5):F1096-102. PubMed ID: 15998841
    [Abstract] [Full Text] [Related]

  • 4. A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia.
    Arcidiacono MV, Cozzolino M, Brancaccio D, Gallieni M, Lesma E, Carelli S, Gorio A, Di Giulio AM.
    J Nephrol; 2007 Nov; 20(2):228-33. PubMed ID: 17514628
    [Abstract] [Full Text] [Related]

  • 5. Parathyroid growth and suppression in renal failure.
    Lewin E, Huan J, Olgaard K.
    Semin Dial; 2006 Nov; 19(3):238-45. PubMed ID: 16689976
    [Abstract] [Full Text] [Related]

  • 6. Pathogenesis of parathyroid hyperplasia in renal failure.
    Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A.
    J Nephrol; 2005 Nov; 18(1):5-8. PubMed ID: 15772917
    [Abstract] [Full Text] [Related]

  • 7. Pathogenic mechanisms for parathyroid hyperplasia.
    Dusso AS, Sato T, Arcidiacono MV, Alvarez-Hernandez D, Yang J, Gonzalez-Suarez I, Tominaga Y, Slatopolsky E.
    Kidney Int Suppl; 2006 Jul; (102):S8-11. PubMed ID: 16810310
    [Abstract] [Full Text] [Related]

  • 8. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.
    Cozzolino M, Lu Y, Finch J, Slatopolsky E, Dusso AS.
    Kidney Int; 2001 Dec; 60(6):2109-17. PubMed ID: 11737585
    [Abstract] [Full Text] [Related]

  • 9. The induction of C/EBPβ contributes to vitamin D inhibition of ADAM17 expression and parathyroid hyperplasia in kidney disease.
    Arcidiacono MV, Yang J, Fernandez E, Dusso A.
    Nephrol Dial Transplant; 2015 Mar; 30(3):423-33. PubMed ID: 25294851
    [Abstract] [Full Text] [Related]

  • 10. Transforming growth factor alpha and mouse models of human breast cancer.
    Humphreys RC, Hennighausen L.
    Oncogene; 2000 Feb 21; 19(8):1085-91. PubMed ID: 10713694
    [Abstract] [Full Text] [Related]

  • 11. Vitamin D analogs as therapeutic agents: a clinical study update.
    Wu-Wong JR, Tian J, Goltzman D.
    Curr Opin Investig Drugs; 2004 Mar 21; 5(3):320-6. PubMed ID: 15083599
    [Abstract] [Full Text] [Related]

  • 12. p21(WAF1) and transforming growth factor-alpha mediate dietary phosphate regulation of parathyroid cell growth.
    Dusso AS, Pavlopoulos T, Naumovich L, Lu Y, Finch J, Brown AJ, Morrissey J, Slatopolsky E.
    Kidney Int; 2001 Mar 21; 59(3):855-65. PubMed ID: 11231340
    [Abstract] [Full Text] [Related]

  • 13. Parathyroid cell growth in patients with advanced secondary hyperparathyroidism: vitamin D receptor, calcium sensing receptor, and cell cycle regulating factors.
    Tokumoto M, Taniguchi M, Matsuo D, Tsuruya K, Hirakata H, Iida M.
    Ther Apher Dial; 2005 Aug 21; 9 Suppl 1():S27-34. PubMed ID: 16109139
    [Abstract] [Full Text] [Related]

  • 14. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma.
    Zhao S, Chen X, Lu X, Yu Y, Feng Y.
    Gynecol Oncol; 2007 Apr 21; 105(1):45-54. PubMed ID: 17240435
    [Abstract] [Full Text] [Related]

  • 15. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ, Slatopolsky E.
    Nat Clin Pract Endocrinol Metab; 2007 Feb 21; 3(2):134-44. PubMed ID: 17237840
    [Abstract] [Full Text] [Related]

  • 16. [The mechanisms of parathyroid hyperplasia and its regression].
    Tokumoto M, Taniguchi M.
    Clin Calcium; 2007 May 21; 17(5):665-76. PubMed ID: 17470994
    [Abstract] [Full Text] [Related]

  • 17. Daily or intermittent calcitriol administration during growth hormone therapy in rats with renal failure and advanced secondary hyperparathyroidism.
    Sanchez CP, He YZ.
    J Am Soc Nephrol; 2005 Apr 21; 16(4):929-38. PubMed ID: 15728789
    [Abstract] [Full Text] [Related]

  • 18. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism.
    Slatopolsky E, Brown A, Dusso A.
    Am J Kidney Dis; 2001 Jan 21; 37(1 Suppl 2):S54-7. PubMed ID: 11158862
    [Abstract] [Full Text] [Related]

  • 19. Vitamin D in normal and pathological parathyroid glands: new prospects for treating hyperparathyroidism (review).
    Buchwald PC, Westin G, Akerström G.
    Int J Mol Med; 2005 Apr 21; 15(4):701-6. PubMed ID: 15754035
    [Abstract] [Full Text] [Related]

  • 20. [Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats].
    Orita H, Hatamura I, Saji F, Shibata M, Shiizaki K, Sakaguchi T, Negi S, Akizawa T.
    Clin Calcium; 2005 Sep 21; 15 Suppl 1():60-63; discussion 63. PubMed ID: 16411340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.